administration of an anti-obesity compound to individuals with renal impairment. The present disclosure relates to weight control in an individual in need thereof by determining the subject's renal sufficiency level and the prescription or administration of a therapeutically effective amount of (r) -8-chloro-1-methyl-2, 3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the subject, provided that the subject has a selected renal sufficiency level from the group consisting of: no renal impairment, renal impairment and moderate renal impairment. furthermore, the description relates to a method for selecting an individual for treatment with (r) -8-chloro-1-methyl-2,3,4,5-tetraido-1h-3-benzazepine or a pharmaceutically salt thereof acceptable, solvate or hydrate thereof from a plurality of subjects in need of weight control by determining the individual's renal sufficiency level and selecting the subject for treatment with (r) -8-chloro-1-methyl-2,3, 4,5-Tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a renal sufficiency level selected from the group consisting of: no renal impairment, mild renal impairment and moderate renal impairment .administração de um composto antiobesidade a indivíduos com comprometimento renal. a presente descrição refere-se para controle de peso em um indivíduo em necessidade dos mesmos determinando o nível de suficiência renal do incivíduo e a prescrição ou administração de uma quantidade terapeuticamente efical de (r)-8-cloro-1-metil-2,3,4,5-tetraidro-1h-3-benzazepina ou um sal farmaceuticamente aceitável, solvato ou hidrato do mesmo ao indivíduo, contando que o indivíduo tenha um nível de suficiência renal selecionado a partir do grupo consistindo em: nenhuma insuficiência renal, insuficiência renal branda e insuficiência renal moderada. além disso, a descrição refere-se a um método para selecionar um indivíduo para o trata
